Leerink Partnrs Boosts Earnings Estimates for Beta Bionics

Beta Bionics, Inc. (NASDAQ:BBNX) – Analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of Beta Bionics in a research note issued to investors on Tuesday, October 28th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn ($1.50) per share for the year, up from their prior estimate of ($1.60). Leerink Partnrs also issued estimates for Beta Bionics’ Q4 2025 earnings at ($0.40) EPS, FY2026 earnings at ($2.02) EPS, FY2027 earnings at ($2.38) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($0.92) EPS.

BBNX has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Beta Bionics in a research note on Wednesday, October 8th. Robert W. Baird set a $23.00 target price on shares of Beta Bionics in a research report on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $32.00 price target (up from $26.00) on shares of Beta Bionics in a research note on Wednesday. Stifel Nicolaus reissued a “buy” rating and set a $31.00 price target (up from $26.00) on shares of Beta Bionics in a research report on Wednesday. Finally, The Goldman Sachs Group raised their price objective on Beta Bionics from $26.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.22.

Beta Bionics Stock Performance

Shares of Beta Bionics stock opened at $27.22 on Friday. The firm has a market cap of $1.20 billion and a PE ratio of -6.23. The business’s 50 day simple moving average is $21.86 and its 200 day simple moving average is $17.23. Beta Bionics has a 52-week low of $8.89 and a 52-week high of $30.47.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, October 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. The firm had revenue of $27.25 million for the quarter, compared to the consensus estimate of $23.92 million. Beta Bionics had a negative return on equity of 35.72% and a negative net margin of 87.89%. Beta Bionics has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Beta Bionics

Institutional investors have recently bought and sold shares of the business. Strs Ohio bought a new stake in Beta Bionics in the first quarter valued at approximately $29,000. CWM LLC acquired a new position in shares of Beta Bionics during the 2nd quarter worth approximately $58,000. Legal & General Group Plc raised its stake in Beta Bionics by 197.4% in the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after acquiring an additional 2,639 shares during the period. Corebridge Financial Inc. acquired a new stake in Beta Bionics during the 1st quarter valued at $79,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Beta Bionics during the first quarter worth $95,000.

Insider Buying and Selling at Beta Bionics

In other news, CFO Stephen Feider sold 4,982 shares of the business’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $21.69, for a total transaction of $108,059.58. Following the transaction, the chief financial officer directly owned 44,041 shares in the company, valued at $955,249.29. The trade was a 10.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Hopman sold 11,411 shares of the company’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $20.56, for a total transaction of $234,610.16. Following the completion of the sale, the insider directly owned 31,215 shares in the company, valued at approximately $641,780.40. The trade was a 26.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 68,901 shares of company stock worth $1,314,543 over the last ninety days.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.